Particulate Risk Prompts Gilead Sciences to Recall Vistide Injections

Posted on

Vistide (cidofovir injection) from lot number B120217A is being recalled by Gilead Sciences.  Certain vials were shown to contain particulates, and thus those versions of the injection with an expiration date of May 2015 are being recalled.  No one has reported sustaining any type of adversity in conjunction with this item, but the company takes pains to note that the presence of particulates in an injectable substance could cause severe health woes.  The drug, which is used to treat cytomegalovirus retinitis in persons who suffer from AIDS, should be inspected, and those versions shown to be from the aforementioned lot ought not to be used.  Patients who think they may have received the item should speak with their doctors.

Click here to learn more about the recall.